This article is more than 5 years old. Information may no longer be current.

Ten takeaways from the AACR Annual Meeting

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

This year’s American Association for Cancer Research Annual Meeting — titled “Research Propelling Cancer Prevention and Cures” — featured many studies that showed dramatic improvements and promising new therapies across cancers, conducted by the nation’s leading researchers and clinicians.

HemOnc Today presents 10 updates presented at the American Association for Cancer Research Annual Meeting that may affect your practice.

• International and private sector collaboration, as well as the $1.8 billion in federal funding directed toward the NIH as part of the 21st Century Cures Act, are two major accomplishments of the national cancer moonshot initiative achieved in the past year, former Vice President Joe Biden said during a presentation. Read more.
• The addition of investigational immunotherapy indoximod (NLG-8189, NewLink Genetics) to pembrolizumab (Keytruda, Merck) conferred superior response rates in patients with advanced melanoma, according to interim results of a phase 2 clinical trial. Read more.
• Adults who take low-dose aspirin over an extended period demonstrated lower mortality from many cancers, including breast cancer, prostate cancer and lung cancer. Read more.
• Nivolumab (Opdivo, Bristol-Myers Squibb) led to a 5-year survival rate much higher than historical rates in patients with advanced non–small cell lung cancer, according to long-term survival data. Read more.
• The burden of cancer in HIV–positive patients is projected to decrease by 2030, mostly driven by declines in non-Hodgkin lymphoma and Kaposi sarcoma. Read more.
• The combination of trastuzumab (Herceptin, Genentech) plus lapatinib (Tykerb, Novartis) appeared clinically beneficial for patients with treatment-refractory HER-2–positive metastatic colorectal cancer, according to results of the phase 2 HERACLES trial. Read more.
• Twelve percent of childhood cancer survivors harbored mutations that significantly increased their risk for developing subsequent neoplasms. Read more.
• Patients with triple-negative breast cancer who responded to atezolizumab (Tecentriq, Genentech) experienced longer OS than patients who did not respond or used other treatments, according to data from a phase 1a clinical trial. Read more.
• Patients with advanced melanoma derived benefit from a combination of ipilimumab (Yervoy, Bristol-Myers Squibb) and Coxsackievirus A21 (Cavatak, Viralytics), according to a phase 1b clinical trial. Read more.
• Clinical response to neratinib (PB272, Puma Biotechnology) varied by tumor and HER-2 mutation type, according to results from the global, multicenter phase 2 SUMMIT trial. Read more.